Clinical trials: Dalteparin
Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis
Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.
Dose of anticoagulant prophylaxis in patients with continuous veno-venous hemodiafiltration may be insufficient to keep anti-Xa factor activity in prophylactic range.
- Trial name
- NCT04671160
- Testing
- Assessment the activity of anti-Xa factor.
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Gdansk
Venous Thromboembolism, Pulmonary Embolism
Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage
The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral…
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Intracerebral Hemorrhage, Deep Vein Thrombosis
- Trial name
- NCT06753786
- Testing
- Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission., Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Pirogov Russian National Research Medical University
Pneumonia
Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating…
- Trial name
- NCT01532544
- Testing
- Ilomedin and Integrilin, low molecular weight heparin.
- Where
- 4 sites in Denmark, Finland
- Volunteers
- 5 people
- Sponsor
- Thrombologic ApS
Venous Thromboembolism (VTE), Postpartum
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery).
- Trial name
- SHINE (NCT07140211)
- Testing
- Low-dose low-molecular-weight heparin
- Where
- 9 sites in Switzerland
- Volunteers
- 9,200 people
- Sponsor
- Marc Blondon
Venous Thromboembolism
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
- Trial name
- NCT01046903
- Testing
- Fragmin® (Dalteparin Sodium)
- Volunteers
- 503 people
- Sponsor
- Pfizer
Renal Failure
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
The purpose of this study is to determine whether the heparin-coated dialysis filter is superior to a conventional filter during hemodialysis in twelve stable, chronic hemodialysis (HD) patients.
- Trial name
- NCT01388270
- Testing
- a pre-heparin-coated hemodialysis filter; Hepran
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Oslo University Hospital
Differences in Laboratory Coagulation Parameters
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery.
- Trial name
- NCT00986635
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Coronary Artery Disease
Canadian Anticoagulant Percutaneous Coronary Intervention Registry
Advances in mechanical intervention (PCI) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease.
- Trial name
- CAPCIR (NCT00773006)
- Where
- Canada
- Volunteers
- 747 people
- Sponsor
- University of Alberta
Major Orthopaedic Surgery and Renal Impairment
Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
Fondaparinux is an antithrombotic agent having already received a regulatory approval by the European Authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hip replacement (THR), total…
- Trial name
- PROPICE (NCT00555438)
- Testing
- fondaparinux 1.5 mg/day
- Where
- 29 sites in France
- Volunteers
- 451 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pain, Satisfaction, Patient
The Effect of Local Cold Application and ShotBlocker Use in Subcutaneous Injection on Injection Pain and Patient Satisfaction
The research was conducted as a single-blind, randomized controlled, experimental study to determine the effect of ShotBlocker and local cold application on pain and patient satisfaction in subcutaneous heparin injection.
- Trial name
- NCT06563648
- Testing
- shotblocker, local cold application
- Where
- Turkey (Türkiye)
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Bornova No. 25 Mevlana Family Health Center
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
Antiphospholipid Syndrome
The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations
The primary objective of this study is to evaluate plasmatic concentrations of free PGF and sFlt1 for blood samples taken before a first low-molecular-weight-heparin injection and also for blood samples taken on the 4th day of…
- Trial name
- NOH-ANGIO (NCT02855047)
- Where
- France
- Volunteers
- 513 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Coagulation Disorder
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
A single centre, open-label study to assess the effects of VMX-C001 in combination with an oral FXa DOAC on the efficacy of Unfractionated Heparin (UFH) and of VMX-C001 alone on the efficacy of Low Molecular Weight Heparin (LMWH)…
- Trial name
- NCT06517563
- Testing
- VMX-C001, Rivaroxaban, UFH
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19 Acute Respiratory Distress Syndrome, Hypoxemia
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
This is an investigator initiated, single-center, open-label, Phase IIb clinical trial with 40 patients (for a total of 80 patients) to assess efficacy of Low molecular weight heparin using soft mist inhaler in the treatment of…
- Trial name
- NCT04990830
- Testing
- Inhaled Low molecular weight heparin, Standard Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Istanbul University
Cardiac Arrhythmias, Hemorrhage
Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation
Approximately 2 million patients in North America are currently treated with the blood thinner warfarin. These patients have every year more than 200,000 invasive procedures, for which warfarin must be stopped to avoid bleeding…
- Conditions
- Cardiac Arrhythmias, Hemorrhage, Thromboembolism
- Trial name
- PACEBRIDGE (NCT02094157)
- Testing
- Tapered warfarin regimen, Bridged regimen Low-molecular-weight heparin
- Where
- 2 sites in Canada
- Volunteers
- 173 people
- Sponsor
- McMaster University
Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis
Management of Superficial Thrombophlebitis
The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial…
- Conditions
- Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
- Trial name
- NCT00264381
- Testing
- Dalteparin sodium injection
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Lymphoma, Thromboembolism
Heparin or Enoxaparin in Patients With Cancer
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor.
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004875
- Testing
- enoxaparin, heparin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Recurrent Abortion
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with…
- Trial name
- NCT01051778
- Testing
- enoxaparin 40mg plus low dose aspirin, Heparin calcium5,000 U twice daily plus low dose aspirin
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Liver Cirrhosis, Portal Hypertension
Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction
Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction is defined as a loss of decompression of the portal venous system due to occlusion or stenosis of the TIPS.
- Trial name
- NCT03171727
- Testing
- low molecular weight heparin
- Where
- China
- Volunteers
- 117 people
- Sponsor
- West China Hospital